Rhythm Pharmaceuticals In... (RYTM)
NASDAQ: RYTM
· Real-Time Price · USD
62.12
0.13 (0.21%)
At close: Jun 23, 2025, 3:59 PM
60.77
-2.17%
After-hours: Jun 23, 2025, 06:30 PM EDT
0.21% (1D)
| Bid | 60.76 |
| Market Cap | 3.95B |
| Revenue (ttm) | 136.86M |
| Net Income (ttm) | -170.02M |
| EPS (ttm) | -2.8 |
| PE Ratio (ttm) | -22.19 |
| Forward PE | -44.55 |
| Analyst | Strong Buy |
| Ask | 64.1 |
| Volume | 169,460 |
| Avg. Volume (20D) | 721,033 |
| Open | 61.50 |
| Previous Close | 61.99 |
| Day's Range | 61.20 - 62.43 |
| 52-Week Range | 39.46 - 69.89 |
| Beta | 2.30 |
About RYTM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RYTM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RYTM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Rhythm Pharmaceuticals Inc. is scheduled to release its earnings on Aug 5, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+5.04%
Rhythm Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
2 months ago
+17.06%
Rhythm Pharmaceuticals shares are trading higher after the company announced that the Phase 3 TRANSCEND trial met its primary endpoint.
2 months ago · seekingalpha.com
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity DisorderRhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmel...
